XIENCE Skypoint Better Expansion, Deliverability

THE WORLD'S LEADING DRUG-ELUTING STENTS (DES), WITH UNPARALLELED CLINICAL OUTCOMES¹

XIENCE™ Skypoint

XIENCE™ Skypoint

XIENCE Skypoint™ Stent: Better Expansion, Excellent Deliverability, and Trusted Patient Outcomes^2-4

As the latest generation in the XIENCE™ family of stents, the stent platform that consistently delivers successful patient outcomes – not only in the cath lab, but also long-term.⁴ This stent also offers:

The broadest expansion range among XIENCE™ Stents²
The largest size range for a single XIENCE™ product, from 2 mm to 5 mm in diameter and from 8 mm to 48 mm in length²

Stent Choice Matters

During percutaneous coronary interventions (PCI), small differences between stents can be the determining factor for the patient’s acute and long-term outcomes.⁴ XIENCE Skypoint™ Stent has a number of new features that offer broader treatment options to interventional cardiologists (ICs).

Updated features include:

Larger stent expansion and enhanced stent design²
Slimmer catheter profile with integrated one-piece shaft⁵
Low crossing forces and excellent pushability⁶
Improved catheter hub⁵
Improved stent design for 48-mm sizes⁷
Now available in 4.5 and 5.0 mm diameter stent sizes⁸

These new features can help clinicians treat the increasingly wide range of lesions encountered in real-world patients.

XIENCE Skypoint™ Stent Retains Proven Design Elements

Compared to other DES, several key factors account for XIENCE™ Stent’s unparalleled clinical outcomes.¹

Innovative Stent Design:

The XIENCE™ Stent is designed to conform to vessel anatomy,⁸ as well as to reduce inflammation and minimize thrombogenicity.⁹ Get more details about the stent design.

Anti-Thrombotic Fluoropolymer:

Unlike other stents’ polymer coatings, the Abbott fluoropolymer interacts with blood proteins in a manner that reduces thrombus formation.⁹ View the visual evidence of fluoropolymer safety—significantly less inflammation and thrombus formation—compared to competitors’ stents.

Market-Leading Everolimus:

The choice for XIENCE™ Stent is the drug everolimus. This broadly therapeutic drug is safe and stable over the long term.¹⁰ See how the everolimus elution correlates to the restenosis cascade.

TAKE A DEEPER LOOK INTO XIENCE SKYPOINT^TM STENTS

See more detail about XIENCE Skypoint™ Stent expansion, deliverability, and successful patient outcomes, not only during the PCI but far into the future.⁴

Expansion

Deliverability

Trusted patient outcomes

Abbott’s Coronary Intervention Portfolio

XIENCE™ Sierra Stent >

PressureWire™ X Guidewire >

QUANTIEN™ System >

OPTIS™ Imaging System >

Coroventis‡ CoroFlow‡ Cardiovascular System >

References

Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
Data on file at Abbott.
Data on file at Abbott—3.0 x 18 mm or 20 mm stents tested using a simulated arterial model. Comparison is between XIENCE Skypoint™ Stent, XIENCE Sierra™ Stent, Synergy^ǂand Resolute Onyx^ǂ. Push efficiency comparison is between XIENCE Skypoint™ 48-mm Stent, XIENCE Xpedition™ 48-mm Stent and Synergy^ǂ 48 mm.
Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333.
Data on file at Abbott.
Data on file at Abbott. Crossing force comparison is between XIENCE Skypoint™ Stent, Synergy^ǂ and Resolute Onyx^ǂ—3.0 x 18 mm or 20 mm stents tested. Push efficiency comparison is between XIENCE Skypoint™ Stent, XIENCE Xpedition™ Stent, and Synergy^ǂ – 3.0 x 48 mm for all stents tested.
Data on file at Abbott.
Colombo A, et al. J Am Coll Cardiol. 2002;40:1021-1033.
Jinnouchi H, et al. J Am Coll Cardiol. 2019;74:(Suppl B):TCT-291.
Data on file Abbott.

MAT-2305695 V2.0

LOG OUT

Are you sure want to log out from the site?

XIENCE™ FAMILY OF DRUG ELUTING STENTS

XIENCE Skypoint™ Stent: Better Expansion, Excellent Deliverability, and Trusted Patient Outcomes^2-4

Stent Choice Matters